Home Cart Sign in  
Chemical Structure| 1234480-50-2 Chemical Structure| 1234480-50-2

Structure of XMD8-92
CAS No.: 1234480-50-2

Chemical Structure| 1234480-50-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

XMD8-92 is an inhibitor of ERK5/BMK1. The Kd values for BMK1, DCAMKL2, PLK4 and TNK1 are 80 nM, 190 nM, 600 nM and 890 nM respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of XMD8-92

CAS No. :1234480-50-2
Formula : C26H30N6O3
M.W : 474.55
SMILES Code : O=C1C2=CC=CC=C2N(C)C3=NC(NC4=CC=C(N5CCC(O)CC5)C=C4OCC)=NC=C3N1C
MDL No. :MFCD18782742
InChI Key :QAPAJIZPZGWAND-UHFFFAOYSA-N
Pubchem ID :46843772

Safety of XMD8-92

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of XMD8-92

MAPK

Isoform Comparison

Biological Activity

Target
  • BET

    BRD4 (1), Kd:170 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-231 2.5, 5, 10 μM 24 hours To investigate the inhibitory effect of XMD8-92 on ERK5 phosphorylation, results showed that XMD8-92 significantly inhibited ERK5 phosphorylation. PMC11842588
MDA-MB-468 2.5, 5, 10 μM 24 hours To investigate the inhibitory effect of XMD8-92 on ERK5 phosphorylation, results showed that XMD8-92 significantly inhibited ERK5 phosphorylation. PMC11842588
BMDMs 10 μM 1 hour Inhibited ERK5 S496 phosphorylation and reduced mtROS production PMC10357365
HeLa cells 240 nM XMD8-92 exhibited high selectivity to BMK1 in vitro, and it could block EGF-induced activation of BMK1. PMC3107913
KCL22 cells 10 µM 3 days Reduced the growth of KCL22 and K562 cells, and caused cell cycle arrest in G0/G1 phase PMC6178886
K562 cells 10 µM 3 days Reduced the growth of KCL22 and K562 cells, and caused cell cycle arrest in G0/G1 phase PMC6178886
Primary CML cells 10 µM 3 days Induced apoptosis in primary CML cells, but did not significantly affect cell cycle distribution PMC6178886

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice MDA-MB-231 xenograft model oral 15 mg/kg Administered on days 1, 3, and 5, continued for 9 weeks To evaluate the antitumor efficacy of XMD8-92 in vivo, results showed that XMD8-92 monotherapy had limited efficacy in inhibiting tumor growth, with a tumor inhibition rate of 7.75%. PMC11842588
Mice Lung and cervical xenograft tumor models Oral 40 mg/kg/day Once daily for seven days XMD8-92 blocked the growth of lung and cervical xenograft tumors in both immunocompetent and immunodeficient mice, with an inhibition rate of 95%. PMC3107913
BALB/c mice Tobacco smoke-induced gastric epithelial-mesenchymal transition model Intraperitoneal injection 200 mg/kg body weight Once daily for 8 weeks To investigate the inhibitory effect of XMD8-92 on tobacco smoke-induced gastric epithelial-mesenchymal transition. Results showed that XMD8-92 significantly inhibited tobacco smoke-induced ERK5 activation and reversed the expression changes of epithelial-mesenchymal transition markers. PMC4963860
Mice CML mouse model Intraperitoneal injection 2 mg/kg body weight Every other day for 12 weeks Reduced the number of GFP+ (BCR/ABL-expressing) cells in BM and PB of CML mice, but did not significantly affect non-leukemic cell numbers PMC6178886
Mice STZ-induced diabetic model Subcutaneous injection 200 mg/kg body weight Once daily for 8 weeks XMD8-92 significantly decreased diabetes-mediated retinal inflammation, VEGF production, and oxidative stress, halted the degradation of ZO-1, and ablated diabetes-mediated vascular leakage and capillary degeneration PMC8385489

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.11mL

0.42mL

0.21mL

10.54mL

2.11mL

1.05mL

21.07mL

4.21mL

2.11mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories